Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. Their approach includes developing antibiotic candidates with a Gram-positive selective spectrum that blocks the active site of specific bacterial enzymes, inhibiting DNA replication. The company's R&D pipeline targets various Gram-positive bacteria such as MRSA and drug-resistant Streptococcus pneumoniae. Acurx is committed to addressing significant unmet medical needs in the antibiotic space.